PatentsDB

Membrane transporter NaPi2b (SCL34A2) epitope antibodies

US9045533B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9045533-B2
Application numberUS-201314037504-A
CountryUS
Kind codeB2
Filing dateSep 26, 2013
Priority dateJan 29, 2008
Publication dateJun 2, 2015
Grant dateJun 2, 2015

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

First claim

Opening claim text (preview).

What is claimed is: 1. An isolated nucleic acid which comprises a sequence encoding an antibody which specifically binds the extracellular region of SLC34A2 having a heavy chain and a light chain wherein the heavy chain variable region comprises the CDRs as set out in SEQ ID NOs: 26-28 and the light chain variable region comprises the CDRs as set out in SEQ ID NOs: 31-33. 2. The isolated nucleic acid of claim 1 which comprises a sequence encoding an antibody h…

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

View patent family 40756958

External sources

Next steps

Free tools are coming soon. Tell us what you want to track and we'll notify you.

Get alerts for this patentView on Google Patents

Request deeper analysis

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9045533B2 cover?
The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34…
Who is the assignee on this patent?
Ritter Gerd, Yin Beatrice, Murray Anne, and 10 more
What technology area does this patent fall under?
Primary CPC classification C07K16/18. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 02 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).